CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis. In addition, the company's LEAP product candidates include CEL-2000; CEL-4000; and CEL-5000 that are in preclinical trials for potential rheumatoid arthritis therapeutic treatments. CEL-SCI Corporation has a strategic partnership with Saudi Arabian Pharma Company for Multikine in the treatment of head and neck cancer. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.…
CEL-SCI’s Dr. Eyal Talor Receives Second International Keynote Invitation on Multikine Head and Neck Cancer Research
CEL-SCI (NYSEAMERICAN: CVM) is listed on NYSE American, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector.
The shares were at 1.210 USD on 20 November 2026, down 85.9% over 52 weeks. Its 52-week range is 0.8900 USD to 8.430 USD: the price is 85.6% below the high and 36.0% above the low.
Its market capitalisation is 21.28M USD.
CEL-SCI reports return on equity of -159.2% and an operating margin of 0.0%.
Its debt exceeds its cash by 1.36M USD, a debt-to-equity ratio of 0.59. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.